FI911537A0 - Matris med immunomodulerande aktivitet. - Google Patents

Matris med immunomodulerande aktivitet.

Info

Publication number
FI911537A0
FI911537A0 FI911537A FI911537A FI911537A0 FI 911537 A0 FI911537 A0 FI 911537A0 FI 911537 A FI911537 A FI 911537A FI 911537 A FI911537 A FI 911537A FI 911537 A0 FI911537 A0 FI 911537A0
Authority
FI
Finland
Prior art keywords
pct
adjuvants
date
matrix
saponins
Prior art date
Application number
FI911537A
Other languages
English (en)
Finnish (fi)
Inventor
Bror Morein
Karin Loevgren
Kristian Dalsgaard
Jan Thurin
Bo Sundquist
Original Assignee
Bror Morein
Karin Loevgren
Kristian Dalsgaard
Jan Thurin
Bo Sundquist
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE8901027A external-priority patent/SE8901027D0/xx
Priority claimed from SE8902780A external-priority patent/SE8902780D0/xx
Application filed by Bror Morein, Karin Loevgren, Kristian Dalsgaard, Jan Thurin, Bo Sundquist filed Critical Bror Morein
Publication of FI911537A0 publication Critical patent/FI911537A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
FI911537A 1988-09-30 1991-03-28 Matris med immunomodulerande aktivitet. FI911537A0 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25157688A 1988-09-30 1988-09-30
SE8901027A SE8901027D0 (sv) 1989-03-22 1989-03-22 Triterpenoider
SE8902780A SE8902780D0 (sv) 1989-08-16 1989-08-16 Corncerning qa-matrix
PCT/SE1989/000528 WO1990003184A1 (en) 1988-09-30 1989-09-28 Matrix with immunomodulating activity

Publications (1)

Publication Number Publication Date
FI911537A0 true FI911537A0 (fi) 1991-03-28

Family

ID=27355484

Family Applications (1)

Application Number Title Priority Date Filing Date
FI911537A FI911537A0 (fi) 1988-09-30 1991-03-28 Matris med immunomodulerande aktivitet.

Country Status (15)

Country Link
US (1) US5679354A (pt)
EP (1) EP0436620B1 (pt)
JP (1) JP2501650B2 (pt)
AT (1) ATE109662T1 (pt)
AU (1) AU632067B2 (pt)
CA (1) CA1338888C (pt)
DE (1) DE68917474T2 (pt)
DK (1) DK175470B1 (pt)
ES (1) ES2029758A6 (pt)
FI (1) FI911537A0 (pt)
HU (1) HUT56722A (pt)
IE (1) IE65428B1 (pt)
NZ (1) NZ230747A (pt)
PT (1) PT91856B (pt)
WO (1) WO1990003184A1 (pt)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291228B1 (en) 1988-08-03 2001-09-18 Vericore Limited Vaccine
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
JP4129544B2 (ja) * 1993-03-29 2008-08-06 ファイザー・インク サポニンアジュバント使用の多成分系クロストリジウム・ワクチン
NL9301690A (nl) * 1993-08-12 1995-04-18 Seed Capital Investments Verbindingen met adjuvans-activiteit.
WO1995009179A1 (en) * 1993-09-30 1995-04-06 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
AU686891B2 (en) * 1994-10-12 1998-02-12 Iscotec A.B. Saponin preparations and use thereof in iscoms
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US20010053365A1 (en) * 1995-04-25 2001-12-20 Smithkline Beecham Biologicals S.A. Vaccines
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
CN1165628A (zh) * 1996-02-14 1997-11-26 浙江农业大学 茶油饼中提取三萜类皂素作为添加剂的应用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
NZ500779A (en) * 1997-05-20 2001-06-29 Galenica Pharmaceuticals Inc Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
AUPO732997A0 (en) 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
FR2781055B1 (fr) * 1998-07-09 2000-10-13 Immunotech Sa Reactif et methode pour la permeabilisation et l'identification des erythrocytes
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2000009075A2 (en) 1998-08-14 2000-02-24 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
US6649170B1 (en) * 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
ATE376825T1 (de) * 1999-09-24 2007-11-15 Glaxosmithkline Biolog Sa Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
EP1239876B1 (en) * 1999-11-19 2008-07-30 Csl Limited Hcv vaccine compositions
US8163289B2 (en) * 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
AU2002250293B2 (en) 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
WO2002080981A2 (en) 2001-04-04 2002-10-17 Nordic Vaccine Technology A/S Polynucleotide binding complexes comprising sterols and saponins
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US6861410B1 (en) 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003300831A1 (en) * 2002-12-11 2004-06-30 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
US20050287170A1 (en) * 2002-12-11 2005-12-29 Hawaii Biotech, Inc. Subunit vaccine against West Nile viral infection
JP4917263B2 (ja) * 2002-12-23 2012-04-18 バイカル インコーポレイテッド 核酸／ブロックコポリマー／陽イオン性界面活性剤複合体を凍結乾燥する方法
EP1581201A4 (en) * 2002-12-23 2011-03-30 Vical Inc METHOD FOR PRODUCING STERILIC DRUGS ON POLYNUCLEOTIDE BASIS
JP2006515024A (ja) * 2003-01-29 2006-05-18 ファイザー・プロダクツ・インク Ｂｏｒｄｅｔｅｌｌａｂｒｏｎｃｈｉｓｅｐｔｉｃａに対するイヌワクチン
SE0300795D0 (sv) * 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
EP1742659B1 (en) * 2004-04-05 2013-03-13 Pah Usa 15 Llc Microfluidized oil-in-water emulsions and vaccine compositions
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006060723A2 (en) * 2004-12-03 2006-06-08 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
US8007806B2 (en) * 2005-01-20 2011-08-30 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
ES2325243B1 (es) 2008-02-27 2011-05-04 Universidad De Granada Antigeno recombinante.
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
DK3056214T3 (da) 2008-06-27 2019-05-13 Zoetis Services Llc Hidtil ukendte adjuvanssammensætninger
MX2011006077A (es) 2008-12-09 2011-09-01 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige.
US20120052088A1 (en) 2009-04-30 2012-03-01 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
NZ598356A (en) 2009-07-30 2014-06-27 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
TR201808222T4 (tr) 2009-09-03 2018-07-23 Pfizer Vaccines Llc PCSK9 aşısı.
CA2777159A1 (en) 2009-10-22 2011-04-28 Universitat Leipzig Detection of a circovirus in calves suffering from bovine neonatal pancytopenia
EP3257525A3 (en) 2009-12-22 2018-02-28 Celldex Therapeutics, Inc. Vaccine compositions
CA2798837A1 (en) 2010-06-07 2011-12-15 Pfizer Inc. Her-2 peptides and vaccines
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
EP3272359A1 (en) 2010-07-23 2018-01-24 Novavax AB Influenza vaccine
WO2012038367A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
EP3251692B1 (en) 2011-05-13 2023-09-27 Zoetis Services LLC Hendra and nipah virus g glycoprotein immunogenic compositions
CN103917559B (zh) 2011-08-22 2018-01-12 肯杰尼公司 艰难梭菌抗体
WO2013051994A1 (en) 2011-10-03 2013-04-11 Moreinx Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
AU2012343981B2 (en) 2011-11-28 2017-09-07 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
CA3170184A1 (en) * 2012-03-12 2013-09-19 Advanced Bioadjuvants, Llc Adjuvant and vaccine compositions
AU2013231423B2 (en) 2012-03-12 2018-10-04 Janssen Vaccines & Prevention B.V. Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
CA2867955C (en) 2012-03-22 2023-02-07 Crucell Holland B.V. Vaccine against rsv
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
NZ630868A (en) 2013-03-08 2017-02-24 Janssen Vaccines & Prevention Bv Acellular pertussis vaccine
US9907846B2 (en) * 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
TR201902513T4 (tr) 2013-04-25 2019-03-21 Janssen Vaccines & Prevention Bv Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
JP6643981B2 (ja) 2013-05-30 2020-02-12 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． インフルエンザウイルスワクチンおよびその使用
EA034653B1 (ru) 2013-06-17 2020-03-03 Янссен Вэксинс Энд Превеншн Б.В. Стабилизированные растворимые f-полипептиды rsv перед слиянием
US10806779B2 (en) 2013-07-02 2020-10-20 Janssen Vaccines & Prevention B.V. Method for preparing virosomes
WO2015000832A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
ES2914176T3 (es) 2013-09-17 2022-06-07 Obi Pharma Inc Composiciones de una vacuna glucídica para inducir respuestas inmunitarias y usos de las mismas en el tratamiento de cáncer
BR112016005948A2 (pt) 2013-09-19 2017-09-26 Zoetis Services Llc adjuvantes com base em óleo
US20160331829A1 (en) 2013-12-16 2016-11-17 Zoetis Services Llc Hendra and nipah virus g glycoprotein immunogenic compositions
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20212335A1 (es) 2014-01-21 2021-12-16 Pfizer Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
WO2015127140A2 (en) 2014-02-19 2015-08-27 Jody Berry Marburg monoclonal antibodies
EP3662928A1 (en) 2014-04-10 2020-06-10 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
MX2017000394A (es) 2014-07-10 2017-11-30 Janssen Vaccines & Prevention Bv Vacunas para virus influenza y usos de las mismas.
EP3207055A1 (en) 2014-10-15 2017-08-23 Xenothera Composition with reduced immunogenicity
MX2017005788A (es) 2014-11-04 2017-08-02 Janssen Vaccines & Prevention Bv Vacunas terapeuticas contra el vph16.
IL252915B2 (en) 2015-01-15 2024-04-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
HUE063288T2 (hu) 2015-01-16 2024-01-28 Zoetis Services Llc Száj és körömfájás betegség vakcina
PL3283634T3 (pl) 2015-04-14 2019-10-31 Janssen Vaccines & Prevention Bv Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
EP3302536A1 (en) 2015-06-03 2018-04-11 Affiris AG Il-23-p19 vaccines
WO2017005844A1 (en) 2015-07-07 2017-01-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
JP2018522885A (ja) 2015-07-07 2018-08-16 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ ＩｇＥ介在性疾患の処置および予防のためのワクチン
RU2721128C2 (ru) 2015-07-21 2020-05-18 Пфайзер Инк. Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения
CA2995740A1 (en) 2015-08-20 2017-02-23 Janssen Vaccines & Prevention B.V. Therapeutic hpv18 vaccines
EP4019044A3 (en) 2015-09-02 2022-08-24 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
JP6670374B2 (ja) 2015-09-03 2020-03-18 ノババックス，インコーポレイテッド 改善された安定性および免疫原性を有するワクチン組成物
MX2018002708A (es) 2015-09-04 2018-08-01 Primatope Therapeutics Inc Anticuerpos anti-cd40 humanizados y usos de los mismos.
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート
JP6884145B2 (ja) 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
CN108738312A (zh) 2015-12-23 2018-11-02 辉瑞公司 Rsv f蛋白突变体
EP3436482A4 (en) 2016-03-29 2020-03-11 OBI Pharma, Inc. ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EA201892250A1 (ru) 2016-04-05 2019-03-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
HUE053027T2 (hu) 2016-04-05 2021-06-28 Janssen Vaccines & Prevention Bv Stabilizált, szolúbilis prefúziós RSV F fehérje, RSV-fertõzés megelõzésében történõ alkalmazásra
BR112018071683A2 (pt) 2016-04-22 2019-02-19 Obi Pharma, Inc. método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
US10517944B2 (en) 2016-05-02 2019-12-31 Janssen Vaccines & Prevention B.V. Therapeutic HPV vaccine combinations
ES2836598T3 (es) 2016-05-30 2021-06-25 Janssen Vaccines & Prevention Bv Proteínas F de RSV prefusión estabilizadas
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US11001858B2 (en) 2016-06-20 2021-05-11 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
KR20230117482A (ko) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
CN110290800A (zh) 2016-11-21 2019-09-27 台湾浩鼎生技股份有限公司 缀合生物分子、医药组合物及方法
KR102459629B1 (ko) 2017-01-20 2022-10-28 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸***疾病的方法和组合物
EA202090738A1 (ru) 2017-09-15 2020-06-10 Янссен Вэксинс Энд Превеншн Б.В. Способ безопасного индуцирования иммунитета против rsv
LT3743106T (lt) 2018-01-23 2022-09-26 Janssen Vaccines & Prevention B.V. Gripo viruso vakcinos ir jų panaudojimo būdai
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
KR20210004959A (ko) 2018-03-19 2021-01-13 노바백스, 인코포레이티드 다가 인플루엔자 나노입자 백신
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
CN113286616A (zh) 2018-05-23 2021-08-20 Adc治疗有限公司 分子佐剂
TW202035444A (zh) 2018-06-27 2020-10-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
BR112021008975A2 (pt) 2018-11-13 2021-08-17 Janssen Vaccines & Prevention B.V. proteínas f do rsv pré-fusão estabilizadas
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
MX2021012991A (es) 2019-04-25 2021-12-10 Janssen Vaccines & Prevention Bv Antigenos de gripe recombinantes.
EP3969044A1 (en) 2019-05-15 2022-03-23 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
KR20220008816A (ko) 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료
CN114430742A (zh) 2019-09-05 2022-05-03 扬森疫苗与预防公司 流感病毒疫苗及其用途
US20230000966A1 (en) 2019-11-01 2023-01-05 Pfizer Inc. Escherichia coli compositions and methods thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
JP2023512519A (ja) 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
CA3173729A1 (en) 2020-02-23 2021-08-26 Pfizer Inc. Escherichia coli compositions and methods thereof
CA3183500A1 (en) 2020-05-11 2021-11-18 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
KR20230009489A (ko) 2020-05-11 2023-01-17 얀센 파마슈티칼즈, 인코포레이티드 안정화된 코로나 바이러스 스파이크 단백질을 암호화하는 rna 레플리콘
US20240189416A1 (en) 2020-05-11 2024-06-13 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
US20230233661A1 (en) 2020-06-29 2023-07-27 Janssen Vaccines & Prevention B.V. Vaccine combination against repiratory syncytial virus infection
MX2023000373A (es) 2020-07-06 2023-02-13 Janssen Pharmaceuticals Inc Proteinas de fusion de proteinas de la espicula de coronavirus estabilizadas.
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
TW202227467A (zh) 2020-10-27 2022-07-16 美商輝瑞大藥廠 大腸桿菌組合物及其方法
CN116744965A (zh) 2020-11-04 2023-09-12 辉瑞大药厂 用于肺炎球菌疫苗的免疫原性组合物
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
JP2024500935A (ja) 2020-12-23 2024-01-10 ゼノセラ 抗感染受動免疫療法における、抗体依存性マクロファージ炎症誘発性サイトカインの放出を治療及び／又は予防するためのその使用のためのブタポリクローナル抗体組成物
WO2022147373A1 (en) 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
MX2023009738A (es) 2021-02-19 2023-08-30 Janssen Vaccines & Prevention Bv Antigenos de rsv fb prefusion estabilizados.
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
KR20230165275A (ko) 2021-04-01 2023-12-05 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 piv3 f 단백질
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023217988A1 (en) 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
WO2024030856A2 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
SE2200142A1 (en) * 2022-12-13 2024-06-14 Savacc Ab Chrisvacc
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024154048A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Vaccines against respiratory diseases
WO2024153674A1 (en) 2023-01-18 2024-07-25 Novavax AB Methods of quantifying saponins present in particles comprising saponin and lipid
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1503388A (en) * 1975-07-01 1978-03-08 Inverni Della Beffa Spa Pharmaceutically active complexes and pharmaceutical compositions containing them
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
EP0231039B1 (en) * 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) * 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3813570A1 (de) * 1988-04-22 1989-11-09 Fraunhofer Ges Forschung Verfahren zum fuegen von werkstuecken aus aufschmelzbarem werkstoff mit laserstrahlung

Also Published As

Publication number Publication date
DK175470B1 (da) 2004-11-01
IE65428B1 (en) 1995-11-01
AU4337489A (en) 1990-04-18
HUT56722A (en) 1991-10-28
EP0436620A1 (en) 1991-07-17
IE893066L (en) 1990-03-30
JPH04501714A (ja) 1992-03-26
DE68917474D1 (de) 1994-09-15
JP2501650B2 (ja) 1996-05-29
DE68917474T2 (de) 1995-03-16
US5679354A (en) 1997-10-21
NZ230747A (en) 1992-05-26
WO1990003184A1 (en) 1990-04-05
AU632067B2 (en) 1992-12-17
DK55891D0 (da) 1991-03-27
DK55891A (da) 1991-05-29
ES2029758A6 (es) 1992-09-01
HU895758D0 (en) 1991-08-28
EP0436620B1 (en) 1994-08-10
PT91856A (pt) 1990-03-30
PT91856B (pt) 1995-07-03
ATE109662T1 (de) 1994-08-15
CA1338888C (en) 1997-02-04

Similar Documents

Publication Publication Date Title
FI911537A0 (fi) Matris med immunomodulerande aktivitet.
DK40484A (da) Polysaccharid/protein-konjugat, fremgangsmaade til fremstilling deraf og dets anvendelse i en vaccine
DK16487A (da) Vacciner til oral indgift
CA2302554A1 (en) Oil in water emulsions containing saponins
DE3787949D1 (de) Sichtvorrichtung und Verfahren zu ihrer Herstellung.
DK1140165T3 (da) Fordbedrede adjuvanssammensætninger baseret på saponin og dermed tilhörende metoder
AU4324996A (en) Novel cyclodextrin-derivatives and methods for the preparation thereof
ID28003A (id) Turunan-turunan adamantana
DE69005813D1 (de) Verfahren und gerät um rotorblätter zu falten und zu verriegeln.
DK145693D0 (da) Viskos carbonhydrid-i-vandig pufferoploesning-emulsion samt fremgangsmaade til fremstilling deraf
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
PT98156A (pt) Um processo de preparacao de uma composicao de vacina
HU9300995D0 (en) Peroral solvent-free medical preparatives with prolonged effect and method for preparing them
PT854924E (pt) Antigenios de leishmania para uso na terapia e diagnostico da leishmaniose
DK84888A (da) Neisseria gonorrhoea-lectin, anvendeligt som vaccine og diagnostisk markoer, og midler til fremstilling af dette lectin
DE69531793D1 (de) Immunogene zubereitungen
FI925649A0 (fi) Karboxivinylpolymerer med newtonsk viskositet
SE9402880D0 (sv) New peptide derivatives
BR9001974A (pt) Aparelho para pressurizar fluidos de poco de descida no poco,aparelho para assentar um obturador inflavel dentro de um poco subterraneo e processo para ativar um dispositivo de obturador inflavel dentro de um poco subterraneo
CA2058958A1 (en) Method of cleansing proteins
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos
ES2117267T3 (es) Metodo para encapsular sustancias en biocapsulas.
DE69114796D1 (de) Antioxydantsystem auf Basis einer basischen Aminosäure und eines Tocopherols.
EP0271964A3 (en) Method for preparing protein hydrolysates soluble in an acid environment, and the hydrolysates obtained
DK191290D0 (da) Extracellulaer exopolymer, fremgangsmaade til fremstilling af samme og farmaceutiske praeparater indeholdende exopolymeren